History
A list of downloadable documents created during development.
Background information
-
-
Appendix A - Decision paper presented to the Institute's Guidance Executive
-
Appendix A - Decision paper presented to the Institute's Guidance Executive (PDF 66 KB)
-
Venous thromboembolism - rivaroxaban: review proposal - February 2012 information
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 212 KB)
-
Venous thromboembolism - rivaroxaban: final appraisal determination
-
Venous thromboembolism - rivaroxaban: final appraisal determination information
-
Venous thromboembolism - rivaroxaban: final appraisal determination
-
Venous thromboembolism - rivaroxaban: final appraisal determination (PDF 89 KB)
-
Venous thromboembolism - rivaroxaban: non-manufacturer submissions
-
Royal College of Nursing
-
-
British Society for Haemostasis and Thrombosis
-
-
Bayer Healthcare
-
-
Venous thromboembolism - rivaroxaban: clarification letters
-
NICE clarification letter 1
-
-
Manufacturer response to clarification letter 1
-
Manufacturer response to clarification letter 1 (PDF 333 KB)
-
NICE clarification letter 2
-
-
Manufacturer response to clarification letter 2
-
-
Venous thromboembolism - rivaroxaban: expert written personal statements
-
Mr Colin Howie
-
-
Professor Mike Laffan
-
-
Eve Knight
-
-
Annya Stevens - Boal
-
-
Venous thromboembolism - rivaroxaban: ERG report
-
Venous thromboembolism - rivaroxaban: ERG report (PDF 190 KB)
Venous thromboembolism - rivaroxaban: final scope
-
Venous thromboembolism - rivaroxaban: final scope
-
Venous thromboembolism - rivaroxaban: final scope (PDF 29 KB)
Venous thromboembolism - rivaroxaban: final matrix of consultees and commentators (list of stakeholders)
-
Venous thromboembolism - rivaroxaban: final matrix of consultees and commentators (list of stakeholders)
-
Venous thromboembolism - rivaroxaban: response to comments on the draft scope
-
Venous thromboembolism - rivaroxaban: response to comments on the draft scope
-
Venous thromboembolism - rivaroxaban: response to comments on the draft scope (PDF 84 KB)
Venous thromboembolism - rivaroxaban: response to comments on the provisional matrix
-
Venous thromboembolism - rivaroxaban: response to comments on the provisional matrix
-
Venous thromboembolism - rivaroxaban: response to comments on the provisional matrix (PDF 22 KB)